FDA Announces Approval of Roflumilast Foam for Seborrheic Dermatitis
The approval of the once-daily, steroid free foam marks the first approval of a drug by the FDA for the skin condition.
Source: hcplive.com
Applied Topically News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Applied Topically. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Applied Topically Today - Breaking & Trending Today
FDA to Review Roflumilast Foam for Seborrheic Dermatitis
If approved, the once-daily foam would be the first topical drug with a new mechanism of action for seborrheic dermatitis in more than two decades.
Source: medscape.com
FDA Accepts Review of Drug Application of Roflumilast Foam for Seborrheic Dermatitis
It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.
Source: hcplive.com